Erasca, Inc. ERAS
Set alert
As of Nov 2, 10:55 AM ET
- YTD
- +276.08%
- 1 year
- +478.10%
- Open
- 14.76
- Prev close
- 14.35
- Mkt cap
- 4.89B
- Vol
- 1.73M
- Avg vol
- 4.40M
- EPS
- -0.95
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.98
- High
- 15.38
- Forward P/E
- -23.04
- Beta
- 0.62
- Short ratio
- 6.69
- Inst. own
- 89.02%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 15.54
- 200-d avg
- 14.97
- 1y target
- 24.11
5D chart
Signals (100)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 10:25 AM | 30 minutes ago |
| SMA: Bullish | Nov 2, 10:20 AM | 35 minutes ago |
| SMA: Bearish | Nov 2, 10:15 AM | 40 minutes ago |
| MACD: Sell Signal | Nov 2, 10:15 AM | 40 minutes ago |
| SMA: Bearish | Nov 2, 10:05 AM | 50 minutes ago |
| RSI: Overbought | Nov 2, 9:30 AM | 1 hour ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| RSI: Oversold | Oct 30, 3:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 2:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:50 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 4 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 6 days ago |
News
4 days ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact…
5 days ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to…
1 week ago businesswire.com
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law.
1 week ago prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact…
1 week ago globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to…
2 weeks ago defenseworld.net
Erasca (NASDAQ:ERAS) Shares Down 5.8% – What’s Next?
Shares of Erasca, Inc. (NASDAQ: ERAS - Get Free Report) fell 5.8% on Friday. The stock traded as low as $13.86 and last traded at $14.0050. Approximately 228,699 shares changed hands during mid-day…
2 weeks ago globenewswire.com
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD)…
4 weeks ago seekingalpha.com
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling trials ahead. Daraxonrasib's FDA approval validates…
1 month ago defenseworld.net
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat reports. One…
1 month ago globenewswire.com
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by…
1 month ago globenewswire.com
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015…
1 month ago globenewswire.com
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its…
1 month ago defenseworld.net
Engineers Gate Manager LP Takes Position in Erasca, Inc. $ERAS
Engineers Gate Manager LP bought a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund…
1 month ago globenewswire.com
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
1 month ago seekingalpha.com
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago globenewswire.com
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); GPGI, Inc., f/k/a CompoSecure, Inc. (NYSE: GPGI); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS): Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their…
1 month ago globenewswire.com
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the…
1 month ago globenewswire.com
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for…
1 month ago defenseworld.net
Frazier Life Sciences Management L.P. Has $457.55 Million Stock Position in Erasca, Inc. $ERAS
Frazier Life Sciences Management L.P. raised its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 1.2% during the undefined quarter, according to the company in its most recent filing with the SEC.…
2 months ago globenewswire.com
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Erasca, Inc. (NASDAQ: ERAS) against certain of its…
-
2 months ago benzinga.com
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $20
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $18 to $20.
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Erasca, Raises Price Target to $21
Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $21.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $22
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $18 to $22.
-
2 months ago benzinga.com
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12)…
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21
Morgan Stanley analyst Sean Laaman maintains Erasca (NASDAQ:ERAS) with a Equal-Weight and raises the price target from $12 to $21.
3 months ago benzinga.com
Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials
Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $550 million stock offering.
-
3 months ago benzinga.com
B of A Securities Maintains Neutral on Erasca, Raises Price Target to $18
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises the price target from $16 to $18.
-
3 months ago benzinga.com
Erasca Plans To Commence $500M Common Stock Offering
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,…
-
3 months ago benzinga.com
Erasca Announces Updated Preliminary ERAS‑0015 Phase 1 Data And Clinical Plans, With Pivotal Lung And Pancreatic Cancer Trials Slated For 2027
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100%Monotherapy has been generally…
5 months ago benzinga.com
This KeyBanc Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Top analysts upgrade MUR, UNH, ESNT, and ERAS stocks. For more rating changes, see analyst ratings page. See what analysts think of UNH stock.
-
5 months ago benzinga.com
B of A Securities Upgrades Erasca to Neutral, Raises Price Target to $16
B of A Securities analyst Alec Stranahan upgrades Erasca (NASDAQ:ERAS) from Underperform to Neutral and raises the price target from $9 to $16.
5 months ago benzinga.com
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
-
5 months ago benzinga.com
Mizuho Maintains Outperform on Erasca, Lowers Price Target to $26
Mizuho analyst Joseph Catanzaro maintains Erasca (NASDAQ:ERAS) with a Outperform and lowers the price target from $28 to $26.
-
5 months ago benzinga.com
Erasca Q1 EPS $(0.60) Misses $(0.22) Estimate
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.22) by 172.73 percent. This is a 445.45 percent decrease over losses of $(0.11)…
-
5 months ago benzinga.com
Erasca Announces Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate ERAS-0015 In Combination With Keytruda
This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the…
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Crude Oil Gains Over 3%; General Motors Earnings Top Views
US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.
6 months ago benzinga.com
CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.
6 months ago benzinga.com
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings
US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63%,…
6 months ago benzinga.com
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines' patent and trade secret allegations.
6 months ago benzinga.com
Rambus Posts Downbeat Q1 Earnings, Joins Erasca, Spotify, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures mixed, Nasdaq down 1%. Rambus Inc (NASDAQ: RMBS) shares fall 15.1% pre-market after reporting mixed Q1 results. Other stocks also down.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 months ago benzinga.com
Why Bed Bath & Beyond Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estimates. KIDZ, CLDI, DRCT, PFSA, KFRC, MLEC, SANM, SEI, DT are also up while VISN, ERAS, AREB, and YAAS are…
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
6 months ago benzinga.com
Erasca Reports Early Phase 1 Results For ERAS-0015 With High Response Rates In KRAS-Mutant Lung And Pancreatic Cancers
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDERobust monotherapy efficacy in 2L KRAS…
-
6 months ago benzinga.com
Revolution Medicines Alleges Patent, Trade Secret, And False Comparison Claims Over ERAS-0015; Erasca Vows Strong Defense
On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. ("RevMed"). In the letter RevMed alleged that (1) the Company's asset ERAS-0015 is "substantially…
-
6 months ago benzinga.com
Erasca To Host Conference Call To Discuss Preliminary Phase 1 Dose Escalation Data For Pan-RAS Molecular Glue ERAS-0015 In Patients With RAS-Mutant Solid Tumors On April 27
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,…
-
6 months ago benzinga.com
Stifel Maintains Buy on Erasca, Raises Price Target to $30
Stifel analyst Laura Prendergast maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $20 to $30.
-
6 months ago benzinga.com
Erasca Narrows ERAS-0015 Phase 1 Data Readout Timeline To Mid-May 2026
On April 21, 2026, Erasca, Inc. (the "Company") narrowed the time period for the anticipated Phase 1 monotherapy data readout for the Company's pan-RAS molecular glue ERAS-0015 from the AURORAS-1 and…
7 months ago benzinga.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…